Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial

IMPORTANCE: Dapagliflozin was recently shown to reduce cardiovascular death or worsening heart failure (HF) events in patients with HF with mildly reduced or preserved ejection fraction in the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (D...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaduganathan, Muthiah, Claggett, Brian L., Jhund, Pardeep, de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S. P., Martinez, Felipe, Shah, Sanjiv J., Desai, Akshay S., Hegde, Sheila M., Lindholm, Daniel, Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J. V., Solomon, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531091/
https://www.ncbi.nlm.nih.gov/pubmed/36190011
http://dx.doi.org/10.1001/jamacardio.2022.3750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531091/
https://www.ncbi.nlm.nih.gov/pubmed/36190011
http://dx.doi.org/10.1001/jamacardio.2022.3750

Ejemplares similares